ONCOCUR is an emerging nanomedicine company with a focus on next generation nanoparticles based precision therapeutics for oncology. Nanoparticle drugs has the potential to work against multi drug resistance deadly cancers, and offers better therapeutic index by selective targeting, lower drug toxicity, greater intracellular availability and gene regulation.
Oncocur develops novel metal and metal oxide nanoparticles based drugs either standalone or therapeutic combinations for the treatment of cancer. Using our strong expertise in nanoscience, pharma and biotech disciplines, we identify and develop innovative and safer chemo-immune therapeutic pre-clinical candidates for advanced cancer care.
Oncocur endeavours these life changing nanotherapeutic interventions available to the patients.